Company Description
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights.
The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.
It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| Country | Netherlands |
| Founded | 1986 |
| IPO Date | Jun 28, 1996 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5,967 |
| CEO | Thierry Bernard |
Contact Details
Address: Hulsterweg 82 Venlo, 5912 PL Netherlands | |
| Phone | 31 77 355 6600 |
| Website | qiagen.com |
Stock Details
| Ticker Symbol | QGEN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001015820 |
| CUSIP Number | N72482123 |
| ISIN Number | NL0015001WM6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thierry Bernard | Chief Executive Officer, MD and Member of Management Board |
| Dr. Roland Sackers | Chief Financial Officer, MD and Member of Management Board |
| Antonio Santos | Senior Vice President and Head of Global Operations |
| John Gilardi | Vice President of Corporate Communications and Investor Relations |
| Stephany Foster | Senior Vice President and Head of Human Resources |
| Dr. Thomas Schweins | Senior Vice President of Life Science Business Area |
| Dr. Thomas Theuringer | Senior Director and Head of External Communications |
| Jean-Pascal Viola | Senior Vice President and Head of Corporate Strategy and Business Development |
| Dr. Jonathan G. Sheldon Ph.D. | Senior Vice President and Head of the QIAGEN Digital Insights Business Area |
| Fernando Beils | Senior Vice President and Head of the Molecular Diagnostics Business Area |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 11, 2024 | 144 | Filing |
| Sep 4, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Aug 2, 2024 | 6-K | Report of foreign issuer |